The Latest Cardiac and Vascular News
NANJING, China, Oct. 22, 2024 /PRNewswire/ — HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for “Allogeneic Human iPSC-derived cardiomyocytes…
Aliso Viejo, CA – October 21, 2024 – Okami Medical today announced the closing of a $32.5M financing led by new investor Vensana Capital and joined by existing investors including U.S. Venture Partners, members of Okami’s board of directors, and other medical device industry veterans. Okami was launched by medical […]
New cardiac CT scanner enhances diagnostic capabilities and reduces wait times for patients across six Georgia locations Caesarea, Israel – Oct. 21, 2024 – Arineta, a leader in advancing cardiovascular imaging solutions, announces the installation of its SpotLight™ Duo cardiac CT scanner at Peachstate Advanced Cardiac and Endovascular (PACE) in […]
BOSTON and NEW YORK, Oct. 21, 2024 /PRNewswire/ — Provident Healthcare Partners (“Provident”), a leading healthcare investment banking firm, announced it has advised Birmingham Heart Clinic (“BHC”) in its partnership with U.S. Heart & Vascular (“USHV”). BHC is a provider of comprehensive…
ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation’s Annual Meeting taking place October 28-29 in Lisbon, Portugal.
Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). The trial enrolled 9,650 people with type 2 diabetes and established cardiovascular disease (CVD) and/or chronic kidney disease (CKD). As part of standard of care, 49% of patients received SGLT2i at some point during the trial.
A First in the Middle East and North Africa
KFSHRC Launches Mobile Stroke Unit to Accelerate Patient Treatment
New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablation MARLBOROUGH, Mass., Oct. 18, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and…
The Birmingham Heart Clinic partnership represents USHV’s 1st in the state. BIRMINGHAM, Ala., Oct. 18, 2024 /PRNewswire/ — US Heart & Vascular (“USHV”), a national provider of support services to cardiovascular physician practices, has partnered with Birmingham Heart Clinic (“Birmingham…
MINNEAPOLIS, Oct. 18, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the American Medical Association (AMA) CPT® Editorial Panel has accepted new Current Procedural Terminology (CPT) Category I codes for baroreflex activation therapy (“Barostim”) to treat the symptoms of heart failure.
